Abbott’s sNDA for new six-month 45-mg formulation of Lupron Depot: FDA accepts for review The U.S.D., vice president, Global Pharmaceutical Advancement, Abbott. ‘Abbott is searching for approval for a new six-month formulation to supply greater comfort and dosing flexibility to physicians and sufferers who could benefit from this medicine.’ Lupron Depot happens to be available in one-month , three-month and four-month depot formulations. Resource Abbott.‘Parents should be extremely reassured,’ said Dr. Laurel Leslie, a Tufts University pediatrician who acquired no role in the analysis but offered on a FDA advisory panel examining medications for ADHD. The scholarly study was sponsored by the FDA and the federal Agency for Healthcare Research and Quality. Online Tuesday by the New England Journal of Medication Results were published. Results from similar studies of these medicines in adults are anticipated soon. More than 5 million children in the U.S.